Latest Breaking News On - Dermatology annual - Page 4 : comparemela.com

Plaque psoriasis patients treated with JNJ-2113 maintain skin clearance up to 1 year

Plaque psoriasis patients treated with JNJ-2113 maintain skin clearance up to 1 year
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesLaura ferrisBygabriellem grassoKristen dowdUniversity of pittsburghAmerican academy of dermatology annual meetingDermatology annualProtagonist therapeutics

Alumis hits stride as TYK2 inhibitor improves psoriasis in ph 2

Alumis hits stride as TYK2 inhibitor improves psoriasis in ph 2
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United statesBristol myers squibbAmerican academy of dermatology annual meetingAmerican academyDermatology annualPsoriasis areaSeverity scoreFierce biotech

Vtama cream achieves consistent efficacy in atopic dermatitis across racial groups

Vtama cream achieves consistent efficacy in atopic dermatitis across racial groups
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesAndrewf alexisKristen dowdBygabriellem grassoDermavant sciencesAmerican academy of dermatology annual meetingDermatology annualWeill cornell medicineAfrican americanAmerican indianAlaska nativeNative hawaiianPacific islander

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 Achieving At Least an ACR 20 Response Compared to 29.2% in the Placebo Group at Week 12 1 − TAK-279.

United statesSan diegoNew orleansUnited kingdomAlan kivitzGreenwood carrieroExchange commissionResearch developmentHealth technology assessmentJournals libraryAmerican college of rheumatologyAmerican academy of dermatology annual meetingTakeda pharmaceutical company limitedArthritis foundationSociety for investigative dermatology annual meetingTakeda pharmaceuticals

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared to Placebo at Week 121 − Based on the.

United statesNew orleansGreenwood carrieroAmerican academy of dermatology annual meetingSociety for investigative dermatology annual meetingTakeda pharmaceutical company limitedExchange commissionTakeda pharmaceuticalsAmerican college of rheumatologyAmerican collegeAndy plumpFiscal yearPsoriasis areaSeverity indexTyrosine kinaseAnnual report